Pretreatment with FK506 improves survival rate and gas exchange in canine model of acute lung injury

T. Koshika, A. Ishizaka, I. Nagatomi, Y. Sudo, Naoki Hasegawa, T. Goto

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The novel effects of FK506 on shock induced by lipopolysaccharide and phorbol myristate acetate (LPS/PMA) were studied using beagles. Five groups were studied: endotoxin shock control group (both 0.5 mg/kg of LPS and 30 μg/kg of PMA, n = 6); methylprednisolone-treated endotoxin shock group (n = 5); FK506-treated endotoxin shock groups in which intravenous infusions of FK506 at 2.5 μg/kg/h (low dose, n 5), 8 μg/kg/h (medium dose, n = 5), and 25 μg/kg/h (high dose, n = 5) were administered, in the control group, the survival rate was 33%. Also, arterial hypoxemia, systemic hypotension, and marked increases in pulmonary vascular resistance (PVR) and wet-to-dry weight ratio (W/D) were observed. FK506 treatment at both medium and high doses significantly attenuated these LPS/PMA-induced physiological changes, and the survival rates were 80 and 100%, respectively. On the other hand, in the methylprednisolone group, no obvious effects were observed. The present study suggests that FK506 could have prophylactic potential against acute lung injury in endotoxin shock.

Original languageEnglish
Pages (from-to)79-84
Number of pages6
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume163
Issue number1
Publication statusPublished - 2001

Fingerprint

Acute Lung Injury
Tacrolimus
Canidae
Shock
Endotoxins
Gases
Methylprednisolone
Tetradecanoylphorbol Acetate
Lipopolysaccharides
Control Groups
Intravenous Infusions
Vascular Resistance
Hypotension
Weights and Measures

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Pretreatment with FK506 improves survival rate and gas exchange in canine model of acute lung injury. / Koshika, T.; Ishizaka, A.; Nagatomi, I.; Sudo, Y.; Hasegawa, Naoki; Goto, T.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 163, No. 1, 2001, p. 79-84.

Research output: Contribution to journalArticle

@article{ca98831b17df4989868a14df0b334dad,
title = "Pretreatment with FK506 improves survival rate and gas exchange in canine model of acute lung injury",
abstract = "The novel effects of FK506 on shock induced by lipopolysaccharide and phorbol myristate acetate (LPS/PMA) were studied using beagles. Five groups were studied: endotoxin shock control group (both 0.5 mg/kg of LPS and 30 μg/kg of PMA, n = 6); methylprednisolone-treated endotoxin shock group (n = 5); FK506-treated endotoxin shock groups in which intravenous infusions of FK506 at 2.5 μg/kg/h (low dose, n 5), 8 μg/kg/h (medium dose, n = 5), and 25 μg/kg/h (high dose, n = 5) were administered, in the control group, the survival rate was 33{\%}. Also, arterial hypoxemia, systemic hypotension, and marked increases in pulmonary vascular resistance (PVR) and wet-to-dry weight ratio (W/D) were observed. FK506 treatment at both medium and high doses significantly attenuated these LPS/PMA-induced physiological changes, and the survival rates were 80 and 100{\%}, respectively. On the other hand, in the methylprednisolone group, no obvious effects were observed. The present study suggests that FK506 could have prophylactic potential against acute lung injury in endotoxin shock.",
author = "T. Koshika and A. Ishizaka and I. Nagatomi and Y. Sudo and Naoki Hasegawa and T. Goto",
year = "2001",
language = "English",
volume = "163",
pages = "79--84",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "1",

}

TY - JOUR

T1 - Pretreatment with FK506 improves survival rate and gas exchange in canine model of acute lung injury

AU - Koshika, T.

AU - Ishizaka, A.

AU - Nagatomi, I.

AU - Sudo, Y.

AU - Hasegawa, Naoki

AU - Goto, T.

PY - 2001

Y1 - 2001

N2 - The novel effects of FK506 on shock induced by lipopolysaccharide and phorbol myristate acetate (LPS/PMA) were studied using beagles. Five groups were studied: endotoxin shock control group (both 0.5 mg/kg of LPS and 30 μg/kg of PMA, n = 6); methylprednisolone-treated endotoxin shock group (n = 5); FK506-treated endotoxin shock groups in which intravenous infusions of FK506 at 2.5 μg/kg/h (low dose, n 5), 8 μg/kg/h (medium dose, n = 5), and 25 μg/kg/h (high dose, n = 5) were administered, in the control group, the survival rate was 33%. Also, arterial hypoxemia, systemic hypotension, and marked increases in pulmonary vascular resistance (PVR) and wet-to-dry weight ratio (W/D) were observed. FK506 treatment at both medium and high doses significantly attenuated these LPS/PMA-induced physiological changes, and the survival rates were 80 and 100%, respectively. On the other hand, in the methylprednisolone group, no obvious effects were observed. The present study suggests that FK506 could have prophylactic potential against acute lung injury in endotoxin shock.

AB - The novel effects of FK506 on shock induced by lipopolysaccharide and phorbol myristate acetate (LPS/PMA) were studied using beagles. Five groups were studied: endotoxin shock control group (both 0.5 mg/kg of LPS and 30 μg/kg of PMA, n = 6); methylprednisolone-treated endotoxin shock group (n = 5); FK506-treated endotoxin shock groups in which intravenous infusions of FK506 at 2.5 μg/kg/h (low dose, n 5), 8 μg/kg/h (medium dose, n = 5), and 25 μg/kg/h (high dose, n = 5) were administered, in the control group, the survival rate was 33%. Also, arterial hypoxemia, systemic hypotension, and marked increases in pulmonary vascular resistance (PVR) and wet-to-dry weight ratio (W/D) were observed. FK506 treatment at both medium and high doses significantly attenuated these LPS/PMA-induced physiological changes, and the survival rates were 80 and 100%, respectively. On the other hand, in the methylprednisolone group, no obvious effects were observed. The present study suggests that FK506 could have prophylactic potential against acute lung injury in endotoxin shock.

UR - http://www.scopus.com/inward/record.url?scp=0035156959&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035156959&partnerID=8YFLogxK

M3 - Article

VL - 163

SP - 79

EP - 84

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 1

ER -